Samjin Pharm to undertake joint ADC R&D with Novelty Nobility

SamjinPharmaceutical announced Wednesday that it has signed a joint research agreement with Novelty Nobility Inc., a company specializing in antibody drug development, to undertake joint development of new antibody-drug conjugate (ADC) materials.

Samjin Pharm will focus on discovering payloads (drugs) of a new mechanism to be used for ADC. Meanwhile, Novelty Nobility will develop a linker-payload conjugate (LP conjugate) that utilizes the company's linker technology called PREXISE-L on Samjin's new payloads.

The LP conjugate to be developed through joint research is expected to maximize the efficacy of the ADC treatment and suppress toxicity as much as possible. Afterward, the two companies will start discovering and developing new ADC materials.

Novelty Nobility is conducting R&D on anticancer drugs, and drugs for ophthalmology and autoimmune diseases through the "one-source multi-use" strategy that applies one antibody to various modalities. The company said it has a fully human antibody platform PREXISE-D using humanized mice and a third-generation linker technology named PREXISE-L.

Write to Jung-Eun Kim at likesmile@hankyung.com